Alzamend Neuro Announces Topline Data For Phase 1 Trial Of AL001 For Dementia Related to Alzheimer's Will Be Delivered Mid-To-Late Dec. 2021; IND Submission For Combined AL002 Phase 1/2 Clinical Trial Expected In Second Quarter Of 2022